Join
Live feed
·
NEWSReleasevia Quantisnow
Ensysce Biosciences Inc. logo

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

ByQuantisnow·Wall Street's wire, on your screen.
ENSC· Ensysce Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ENSC (Ensysce Biosciences Inc.) and more on Quantisnow.